CureVac’s COVID-19 Vaccine Produces Grade 3 Adverse Events

CureVac’s COVID-19 Vaccine Produces Grade 3 Adverse Events

Biopharmaceutical company CureVac NV of Tübingen, Germany has released the interim results of its Phase 1 clinical trial on its experimental CVnCoV vaccine COVID-19. The vaccine, which was given to more than 250 healthy adults 18 to 60 years of age, is based on messenger ribonucleic acid (mRNA) technology.1 2

Unlike traditional vaccines, mRNA vaccines “introduce an mRNA sequence (the molecule which tells cells what to build), which is coded for a disease specific antigen,” wrote Rishma Parpia in an article in The Vaccine Reaction earlier this year.3 She added:

Once produced within the body, vaccine developers say the antigen is recognized by the immune system and stimulates a strong inflammatory response to produce antigens to fight the pathogen. Messenger RNA vaccines are faster and cheaper to produce than traditional vaccines and do not utilize any parts of the pathogenic virus or bacteria.3

According to a press release by CureVac, the CNnCoV vaccine was “generally well tolerated across all tested doses (2-12µg) and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation.” Trial participants were vaccinated intramuscularly with two doses 29 days apart. These included doses of two, four, six, eight and 12 milligrams (µg). Each dose level was given to groups consisting of up to 10 participants who had previously tested positive for the SARS-CoV-2 virus that can cause COVID-19.1

“We are very encouraged by the interim Phase 1 data. It represents a critical milestone in our COVID-19 vaccine program and strongly supports the advancement of our vaccine candidate,” said Dr. Franz-Werner Haas, CEO of CureVac. “Following further data readouts and discussion with regulatory authorities, we remain fully committed and on track to initiate a pivotal Phase 2b/3 trial before the end of 2020.”1

While CureVac reported that it observed no “serious adverse events” related to the CVnCoV vaccine, the company noted that some of the trial participants who received doses of 12 µg experienced Grade 3 adverse events mostly after being injected with the second dose. These reactions included fatigue, headache, chills, muscle pain and fever. CureVac reported that the reactions were “transient” and usually resolved within 24 to 48 hours.1

A Grade 3 adverse event is defined by the U.S. Department of Health and Human Services (HHS) as,

severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care” such as “bathing, dressing and undressing, feeding self, using the toilet, taking medications.” In other words, a Grade 3 adverse event is serious. It is only one grade removed from “life-threatening” (Grade 4) and just two grades from “death” (Grade 5).4 5

CureVac is currently negotiating a deal to provide the European Union (EU) with 225 million doses of CNnCoV, with an option to supply EU countries with an additional 180 million doses, for a total of 405 million doses once the vaccine is approved by European regulatory authorities.2 6




This excellent article by Dr. Mercola reveals how COVID-19 vaccine trials are designed:

Important points:

  • preventing infection is not a criterion for success in any of these trials
  • the only criterion for a successful COVID-19 vaccine is a reduction of COVID-19 symptoms, and even then, the reduction required is minimal
  • many vaccine trials are NOT using inert placebos – making it easier to hide vaccine side-effects
  • AstraZeneca is masking potential side effects by administering the vaccine along with acetaminophen every six hours for the first 24 hours after inoculation. The pain and fever reducer could potentially mask and downplay side effects such as pain, fever, headache or general malaise
  • two trails were paused due to safety concerns
  • 80% of Moderna’s Phase 1 participants receiving the 100 microgram (mcg) dose developed systemic side effects.  100% developed side effects after the second dose
  • CNBC also noted that as companies progressed through clinical trials, several vaccine makers abandoned their highest doses following reports of more severe reactions

Also, before you believe the splashy headlines that Pfizer’s vaccine is 90% effective, the devil’s in the details:

  • Analysis evaluated 94 confirmed cases of COVID-19 out of 43,538 participants.  This means only .2% are reporting. Repeat – only .2%!
  • In approximately 2 months they have not noted any serious safety concerns. This is NOT a long enough time to determine safety.
  • While the study states it will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as prevention against severe COVID-19 disease, IT HASN’T YET DONE SO.  Therefore, they have not yet obtained whether this vaccine does these things at all. 

Please see the following on how this vaccine could damage the immune system, particularly of those chronically infected:

More on the vaccine:

There are already treatments that have proven successful.  No vaccine even needed:  

%d bloggers like this: